Quoin pharmaceuticals announces fda clearance of clinical optimization plan for qrx003 for netherton syndrome

Positive initial data and clean safety profile catalyze optimization plan size of both ongoing clinical trials significantly increased lower dose eliminated from blinded trial dosing frequency changed to twice-daily from once-daily for both trials
QNRX Ratings Summary
QNRX Quant Ranking